ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0476

Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis

Marc Martel1, Lilach Eyal Waldman1, Romina Sotoodeh1, Antonio Vigano1, Yola Moride2, Michelle Canac-Marquis3, Rihab Gamaoun3, Maja Kalaba4, Pierre Beaulieu2, Julie Desroches2, Mark A. Ware4, Jordi Perez3, Yoram Shir3 and Mary-Ann Fitzcharles1, 1McGill University, Montréal, QC, Canada, 2Université de Montréal, Montréal, QC, Canada, 3McGill University Health Centre, Montréal, QC, Canada, 4Canopy Growth Corporation, Montréal, QC, Canada

Meeting: ACR Convergence 2021

Keywords: Anxiety, fibromyalgia, pain, Patient reported outcomes, sleep

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)

Session Type: Abstract Session

Session Time: 11:30AM-11:45AM

Background/Purpose: Fibromyalgia (FM) is characterized by a constellation of symptoms that are often poorly responsive to current treatments, and patients are increasingly turning to medical cannabis (MC) as a strategy to improve pain and well-being. To date, little is known about the factors that may contribute to the perceived benefits of medical cannabis in patients with FM. Given that negative affect (i.e., anxiety, depression) and sleep problems contribute to heightened pain intensity and poor well-being, improvements in these variables might indirectly contribute to MC treatment benefits. Factors contributing to continuation of MC treatment, a surrogate for treatment satisfaction, are also largely unknown. The objectives of the present analyses were: 1) to examine whether changes in negative affect and sleep problems contributed to changes in pain intensity and well-being following initiation of MC; 2) to examine the factors contributing to MC treatment continuation.

Methods: Patients included in this study were part of a prospective, observational, non-comparative registry of adult patients who initiated MC under the supervision of a physician between 2015 and 2018 in Quebec, Canada. Sociodemographic and clinical characteristics were recorded at baseline. MC treatment characteristics (MC products, routes, doses) and symptom variables were assessed during in-clinic visits at baseline and every three months for a period of one year.

Results: Of the 2068 chronic non-cancer pain patients enrolled in this registry, 308 (14.9 %) had FM. The FM sample included 87 % women (mean age: 52.3 ± 12.9 years) and most patients (54.3 %) were using a combination of THC and CBD. Results revealed significant improvements in pain intensity and well-being following initiation of MC (both ps < .05). A multilevel mediation analysis subsequently revealed that reductions in pain intensity were mediated by reductions in negative affect (p < .001) and sleep problems (p < .001). Improvements in well-being were mediated by reductions in negative affect (p < .001) and pain intensity (p < .05). MC was continued by 74%, 58.8%, 39.6%, and 23.1% of FM patients at the 3, 6, 9, and 12-month time points, respectively. The likelihood of treatment discontinuation was higher among patients with higher levels of pain and negative affect (both ps < .05), but was unrelated to the degree of improvement in these symptoms over the course of MC treatment (all ps > .05).

Conclusion: Our findings suggest that reductions in negative affect and sleep problems are important contributors to improvements in pain intensity and well-being among FM patients using MC. Discontinuation of MC was more common among those with higher levels of pain and negative affect but was not related to symptom improvement. These findings are a move towards precision medicine in MC recommendations for treatment of FM.


Disclosures: M. Martel, None; L. Waldman, None; R. Sotoodeh, None; A. Vigano, Canopy Growth, 2, 5, 6, Tilray, 2, 5, 6, Syqe, 1; Y. Moride, Many companies (15+), 1, 2; M. Canac-Marquis, None; R. Gamaoun, None; M. Kalaba, Canopy Growth Corporation, 3; P. Beaulieu, None; J. Desroches, None; M. Ware, Canopy Growth Corporation, 3; J. Perez, Spectrum Therapeutics, 6; Y. Shir, None; M. Fitzcharles, None.

To cite this abstract in AMA style:

Martel M, Waldman L, Sotoodeh R, Vigano A, Moride Y, Canac-Marquis M, Gamaoun R, Kalaba M, Beaulieu P, Desroches J, Ware M, Perez J, Shir Y, Fitzcharles M. Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-pain-reduction-and-improved-well-being-among-fibromyalgia-patients-using-medical-cannabis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-pain-reduction-and-improved-well-being-among-fibromyalgia-patients-using-medical-cannabis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology